Abstract
SIGNIFICANCE Erdafitinib is the first fibroblast growth factor receptor inhibitor approved by the U.S. Food and Drug Administration in April 2019 for ......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
